Suppr超能文献

首次使用 Silk Vista 血流导向装置治疗 60 例连续颅内动脉瘤的多中心经验:技术方面。

First multicenter experience using the Silk Vista flow diverter in 60 consecutive intracranial aneurysms: technical aspects.

机构信息

Interventional Neuroradiology/Endovascular Neurosurgery, Hospital Clínico Universitario de Valladolid, Valladolid, Spain

Radiology, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey.

出版信息

J Neurointerv Surg. 2021 Dec;13(12):1145-1151. doi: 10.1136/neurintsurg-2021-017421. Epub 2021 Apr 8.

Abstract

BACKGROUND

The aim of this study was to assess the technical success and procedural safety of the new Silk Vista device (SV) by evaluating the intraprocedural and periprocedural complication rate after its use in several institutions worldwide.

METHODS

The study involved a retrospective review of multicenter data regarding a consecutive series of patients with intracranial aneurysms, treated with the SV between September 2020 and January 2021. Clinical, intra/periprocedural and angiographic data, including approach, materials used, aneurysm size and location, device/s, technical details and initial angiographic aneurysm occlusion, were analyzed.

RESULTS

60 aneurysms were treated with SV in 57 procedures. 66 devices were used, 3 removed and 63 implanted. The devices opened instantaneously in 60 out of 66 (91%) cases and complete wall apposition was achieved in 58 out of 63 (92%) devices implanted. In 4 out of 66 (6%) devices a partial opening of the distal end occurred, and in 5 (8%) devices incomplete apposition was reported. There were 3 (5%) intraprocedural thromboembolic events managed successfully with no permanent neurological morbidity, and 4 (7%) postprocedural events. There was no mortality in this study. The initial occlusion rates in the 60 aneurysms were as follows: O'Kelly-Marotta (OKM) A in 34 (57%) cases, OKM B in 15 (25%) cases, OKM C in 6 (10%) cases, and OKM D in 5 (8%) cases.

CONCLUSIONS

Our study demonstrated that the use of the new flow diverter Silk Vista for the treatment of intracranial aneurysms is feasible and technically safe.

摘要

背景

本研究旨在评估新型 Silk Vista 装置(SV)的技术成功率和程序安全性,通过评估该装置在全球多个机构使用后的术中及围手术期并发症发生率来实现这一目标。

方法

本研究回顾性分析了 2020 年 9 月至 2021 年 1 月期间,采用 SV 治疗颅内动脉瘤的多中心连续病例系列患者的临床、术中/围手术期及血管造影数据。分析内容包括入路、使用的材料、动脉瘤大小和位置、装置/器械、技术细节以及初始血管造影动脉瘤闭塞情况。

结果

57 例手术中治疗了 60 个动脉瘤。使用了 66 个装置,其中 3 个被取出,63 个被植入。66 个装置中有 60 个(91%)即刻打开,58 个(92%)完全贴合植入的装置实现了完全贴合。在 4 个(6%)装置中出现了远端部分打开的情况,在 5 个(8%)装置中报告了不完全贴合的情况。3 个(5%)装置发生术中血栓栓塞事件,均成功处理,无永久性神经功能缺损,4 个(7%)发生术后事件。本研究无死亡病例。60 个动脉瘤的初始闭塞率如下:O'Kelly-Marotta(OKM)分级 A 为 34 个(57%),OKM 分级 B 为 15 个(25%),OKM 分级 C 为 6 个(10%),OKM 分级 D 为 5 个(8%)。

结论

我们的研究表明,新型血流导向装置 Silk Vista 治疗颅内动脉瘤是可行且技术安全的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/105e/8606442/5a2ca6c22375/neurintsurg-2021-017421f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验